BridgeBio Pharma (BBIO) Earnings Date & Reports

Key Takeaways

• BridgeBio Pharma (BBIO) reported third quarter 2026 total revenue of $353.17 million, up 192.6% year over year and well above Wall Street expectations.
• Diluted earnings per share (EPS) came in at a loss of $0.42, a narrower loss than the roughly $0.56–$0.60 consensus estimate and an improvement from a loss of $0.95 a year earlier.
• U.S. net product revenue for Attruby (acoramidis), the company's treatment for ATTR-CM (transthyretin amyloid cardiomyopathy), reached $253.2 million, up about $31 million sequentially.
• License and services revenue jumped to $79.31 million, boosted by a one-time $75 million regulatory milestone, helping shrink the company's loss from operations to $11.6 million.
• Results were reported after the market close on October 29, 2026, with the stock finishing that session at $70.73.
• For more on BridgeBio's Major News, Today's Price Move, Price Targets, and Forecast, visit the additional pages, and explore Trending AI Robots for automated trading insights.

Earnings Context and Why It Matters

BridgeBio Pharma is a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, and its quarterly results now hinge on the trajectory of Attruby, its therapy for ATTR-CM, a progressive heart condition. Following a rapid launch ramp, investors are watching whether product revenue can keep compounding while the company manages spending across a pipeline poised for additional launches. The third quarter of 2026 also carried a significant milestone payment that lifted total revenue. For a company still reporting operating losses, this report offers a key read on commercial momentum, expense discipline, and the path toward profitability.

Reported Results

BridgeBio Pharma reported total third quarter 2026 revenue of $353.17 million, a 192.6% increase from the prior-year period and ahead of the Zacks Consensus Estimate of $296.58 million and the roughly $281.65 million consensus cited by Investing.com. Net product revenue was $253.35 million, with U.S. Attruby net product revenue of $253.2 million, up approximately $31 million sequentially and $145 million year over year. Royalty revenue was $20.51 million, while license and services revenue surged to $79.31 million, reflecting a one-time $75 million regulatory milestone.

On the bottom line, the company posted a diluted loss of $0.42 per share, an improvement from a loss of $0.95 per share a year earlier and better than consensus estimates that ranged from about $0.56 to $0.60. Loss from operations narrowed to $11.6 million, driven by higher revenue and the milestone payment.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors monitoring companies like BridgeBio Pharma, it offers a structured way to identify setups and signals across the broader market.

Market Reaction and Investor Sentiment

BridgeBio Pharma shares closed at $70.73 on October 29, 2026, down a modest 0.13% on the day the results were released, suggesting investors had already priced in much of the company's commercial momentum. Sentiment heading into the print was broadly positive, supported by strong Attruby sales growth and a consensus price target above $113, with Piper Sandler recently issuing a $120 target. While the revenue and EPS beats reinforced the bull case, the muted same-day move indicates that the market's attention is increasingly turning toward forward guidance and upcoming pipeline catalysts rather than a single quarter's upside.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus first on the continued launch trajectory of Attruby and whether sequential product revenue growth can be sustained. Management has pointed to expanding sales coverage and growing first-line use, but the durability of those trends, alongside payer authorization dynamics, remains a central watch item.

A second area to monitor is spending. BridgeBio is deliberately investing in commercialization while preparing for additional launches, so the balance between revenue growth and operating expense discipline will shape how quickly losses narrow. The company has also signaled upcoming regulatory catalysts, including expected FDA (U.S. Food and Drug Administration) reviews, which could materially influence the product pipeline and long-term revenue outlook.

Finally, the company's cash position and access to capital will be important given ongoing operating losses and a meaningful debt load. Investors will likely track gross-to-net trends for Attruby, royalty contributions from partnered products, and any new milestone or collaboration revenue, all of which affect both top-line growth and the timeline to sustained profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations